LAS VEGAS, Oct. 30, 2023 /PRNewswire/ — The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the Late-Breaking Clinical Trials session at The VEINS conference,…
Other News
Pulsecare Medical’s nsPFA clinical trial receives satisfactory short-term follow-up results
SHENZHEN, China, Oct. 30, 2023 /PRNewswire/ — Pulsecare Medical, an innovative minimally invasive and non-invasive therapeutic technology company, announced today that its nanosecond pulsed field ablation (nsPFA) system for cardiac electrophysiology, the world’s first third-generation…
Cardio Flow Announces Completion of First Commercial Cases of Innovative FreedomFlow Orbital Atherectomy Platform—and Appointment of Chief Operating Officer
ST. PAUL, Minn.–(BUSINESS WIRE)–Cardio Flow, Inc., a privately held commercial-stage medical device company and developer of minimally invasive devices to treat peripheral artery disease (PAD), is pleased to announce the successful completion of its first commercial cases for its FreedomFlow® Orbital Atherectomy Platform following FDA clearance in late September. First Commercial Case Performed by the Cardiovascular Institute of the South (CIS) Cardio Flow announced the successful completion
SS Innovations Appoints Dr. Sonia Shokeen as Head of Quality and Regulatory Affairs
Dr. Shokeen brings over 15 years of medical device experience, including time spent at Johnson & Johnson FORT LAUDERDALE, FL, Oct. 30, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making […]
4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy
Initiated single non-human primate (NHP) safety study evaluating intravenous 4D-310 combined with rituximab/sirolimus (R/S) immunosuppressive regimen Amended INGLAXA protocol to minimize risk of atypical hemolytic uremic syndrome (aHUS) associated with intravenous (IV) AAV dosing, including addition of R/S immunosuppressive regimen 4D-310 combines a novel, targeted next generation AAV vector (C102) […]
Evident Vascular Announces Scientific Advisory Board and New Board Member
SAN JOSE, Calif.–(BUSINESS WIRE)–Evident Vascular, Inc. a medical technology startup developing a next-generation intravascular ultrasound (IVUS) platform leveraging artificial intelligence to enable superior imaging and streamlined workflows, announced today its Scientific Advisory Board and expansion of its Board of Directors. “It is our privilege to have this esteemed group of clinical experts on our Scientific Advisory Board. Their collective expertise and experience innovating new periph
Sirtex Medical Announces Commercial Availability of New LAVA® Liquid Embolic System
Sirtex unveils first-of-its-kind product to treat peripheral vascular hemorrhage WOBURN, Mass., Oct. 27, 2023 /PRNewswire/ — Sirtex Medical (“Sirtex”), a leading manufacturer of interventional treatment solutions, announced today the commercial availability of the LAVA® Liquid Embolic…
Peijia Medical Presents Early Clinical Findings of GeminiOne® TEER Device at TCT 2023
SUZHOU, China, Oct. 27, 2023 /PRNewswire/ — Peijia Medical Limited (Peijia, (9996.HK)), a leading Chinese medical device player in transcatheter structural heart device and neurovascular device, presented its GeminiOne® TEER technology, along with the early clinical experiences of the…
Merit Medical Reports Results for Third Quarter Ended September 30, 2023
Q3 2023 reported revenue of $315.2 million, up 9.8% year-over-year Q3 2023 constant currency revenue* up 9.7% year over year Q3 2023 constant currency revenue, organic* up 7.1% year-over-year Q3 2023 GAAP operating margin of 11.1%, compared to 6.5% in Q3 2022 Q3 2023 non-GAAP operating margin* of 18.3%, compared […]
egnite, Inc. Unveils Research on Mitral Regurgitation at Transcatheter Cardiovascular Therapeutics Conference 2023
ALISO VIEJO, Calif.–(BUSINESS WIRE)– #digitalhealth–Key Findings: Patients with Moderate-to-Severe MR are 3x Less Likely to be Treated Than Patients with Severe MR Despite Similar Mortality



